PUBLIC COMPANY
save$CMPSCOMPASS Pathways plc
$CMPS11.90-0.42%Chesire, GBupdated 2d ago
Compass Pathways, or COMPASS Pathways, is a British pharmaceutical company developing psychedelics as potential medicines. Its main drug candidate, psilocybin (COMP360), is currently in phase 3 clinical trials for treatment-resistant depression. This candidate has received breakthrough therapy status from the U.S. Food and Drug Administration (FDA). It is the most advanced psychedelic drug candidate in development besides Lykos Therapeutics's midomafetamine (MDMA).
community read0 votes
pipeline
1
marketed
0
phase 3
1
catalysts ytd
7
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 3
Upcoming
Recent(90d)
view all catalysts →🐶 Hiring Signal
next earnings Nov 3, 2026
News
- How J&J paved the way for Compass’ coming psychedelic drug launchIn an interview with BioPharma Dive, Compass executives said that, should the FDA approve their treatment, they hope to capitalize on a strategy pioneered by J&J in selling the ketamine spray Sprav…biopharma_dive · 13d ago
- Deep dive: Psychedelics back on FDA’s doorstepBioSpace takes stock of the psychedelic therapeutics space, which is once again on the cusp of its first FDA approval.biospace · 18d ago
- FDA hears input on psychedelics, PDUFA, lung cancer’s next-gen therapies boost survivalThe FDA held a public forum on Monday to discuss the future of psychedelic therapeutics, followed by a meeting on Wednesday regarding recommendations for reauthorizing the Prescription Drug User Fe…biospace · 18d ago
- Stakeholders urge FDA to define data, treatment standards as psychedelic drugs near marketSafety and access were top of mind at Monday’s public hearing exploring the regulation of psychedelic therapies. "The medicine opens the door,” NeuroAlchemy co-founder Michaela Vogt said during the…biospace · 19d ago
- As ‘cultural weight’ of a psychedelic approval looms, FDA hearing focuses on access and safetyAs the FDA marches toward the likely first approval of a psychedelic medicine, the agency today convened a hearing seeking public input on how these drugs should be used, monitored and continuously…fiercebiotech · 20d ago
- Psychedelic therapies ride wave of public favor into FDA hearingHeading into an FDA hearing on Monday regarding the future of psychedelic treatments, public comments show wide support for further exploring the therapeutic potential of these compounds—to match r…biospace · 21d ago
- Compass posts positive psilocybin data; Solstice makes $225M debutPlus news about Luma, Inno Medicine, Schrödinger, Assembly Biosciences, Gilead, Leyden Labs, Navion, Ridge Bio, and Opus Genetics. 📊 Compass Pathways touts one-year data for psilocybin drug: The b…endpoints · 25d ago
- Trump's FDA pick Overton good for psychedelics, new pain meds but bad for vaccines: AnalystsIf confirmed by the Senate, Heidi Overton—officially revealed Wednesday as President Donald Trump’s choice for FDA commissioner—is expected to be a boon for developers of psychedelic therapeutics a…biospace · 1mo ago
- Definium’s LSD asset beats analyst expectations in Phase 3 anxiety readoutIt’s smooth sailing for Definium Therapeutics as the psychedelic biotech charts another win for its LSD candidate, this time in anxiety. The psychedelic previously notched a late-stage victory in d…biospace · 1mo ago
- Replimune finally wins approval, Q2 earnings wrap up, psychedelics stay in spotlightAfter two rejections, Replimune has made it across the regulatory finish line with its advanced melanoma therapy. Meanwhile, the last of the major pharmas, including Eli Lilly and Novo Nordisk, rep…biospace · 1mo ago
Data sources
last refreshed 47m ago
Found something off?
comments(0)
5-min edit window · permanent after that